1 (0.86)	1.04 (0.04)	1.02 (0.68)	1.07 (0.12)	1.16 (0.27)	Atypical Teratoid Rhabdoid Tumor	
0.98 (0.2)	1 (0.96)	0.99 (0.85)	0.97 (0.29)	1.2 (0.27)	CRANIO, ADAM	
0.98 (0.2)	1 (0.96)	0.99 (0.85)	0.97 (0.29)	1.2 (0.27)	Craniopharyngioma	
1 (0.84)	1.01 (0.51)	0.99 (0.68)	1.01 (0.74)	1.04 (0.71)	DMG, H3 K28	
1 (0.83)	0.98 (0.07)	0.97 (0.58)	0.93 (0.02)	0.9 (0.37)	Ependymoma	
1.01 (0.75)	0.98 (0.25)	0.9 (0.05)	0.98 (0.68)	0.83 (0.22)	EPN, PF A	
1.01 (0.52)	0.97 (0.08)	1.16 (0.25)	0.89 (0.01)	1.04 (0.85)	EPN, ST ZFTA	
1.07 (0.04)	0.94 (0.01)	1.04 (0.74)	0.96 (0.34)	0.82 (0.38)	Germ cell tumor	
0.99 (0.79)	0.99 (0.84)	0.92 (0.21)	0.95 (0.12)	0.64 (0.23)	GNG/GNT, BRAF V600E	
0.96 (0.29)	1.01 (0.7)	0.96 (0.38)	0.94 (0.29)	1.2 (0.41)	GNG/GNT, Other alteration	
1 (0.78)	0.99 (0.43)	1.01 (0.65)	0.97 (0.22)	0.77 (0.04)	HGG, H3 WT	
1 (0.44)	1 (0.58)	1 (0.92)	1 (0.66)	0.88 (0.1)	High-grade glioma	EFS Hazard Ratio
1 (0.61)	1 (0.78)	1 (0.98)	1 (0.95)	0.96 (0.75)	LGG, BRAF fusion	
0.99 (0.81)	0.99 (0.58)	0.97 (0.8)	0.9 (0.29)	1.52 (0.1)	LGG, BRAF V600E	0.5
1.01 (0.47)	1 (0.94)	1.08 (0.14)	1 (0.98)	1.07 (0.69)	LGG, Other alteration	0
0.99 (0.66)	1.01 (0.88)	0.9 (0.53)	0.91 (0.45)	0.99 (0.98)	LGG, WT	— 0
1 (0.93)	1 (0.96)	1.01 (0.62)	1 (0.95)	1.07 (0.48)	Low-grade glioma	
0.97 (0.54)	1 (0.83)	0.85 (0.04)	1.09 (0.09)	0.99 (0.97)	MB, Group3	
1.01 (0.71)	0.99 (0.77)	1 (0.93)	1.04 (0.5)	1.02 (0.91)	MB, Group4	
0.96 (0.42)	1 (0.88)	1.17 (0.04)	0.93 (0.03)	1.3 (0.39)	MB, SHH	
1.06 (0.75)	1.1 (0.69)	1.01 (0.94)	1.91 (0.28)	0.31 (0.12)	MB, WNT	
0.99 (0.51)	1 (0.89)	0.98 (0.56)	1.02 (0.37)	0.99 (0.92)	Medulloblastoma	
0.98 (0.24)	1.02 (0.51)	1.07 (0.25)	1.03 (0.68)	0.46 (<0.01)	Meningioma	
1.05 (0.11)	0.97 (0.2)	1.02 (0.74)	0.97 (0.28)	1.12 (0.71)	Mesenchymal tumor	
0.98 (0.23)	1.01 (0.46)	0.97 (0.42)	0.96 (0.23)	1.11 (0.52)	Mixed neuronal-glial tumor	
1.06 (0.04)	1 (0.88)	1.02 (0.72)	0.9 (0.2)	0.86 (0.85)	Schwannoma	
PC1	PC2	PC3	PC4	PC5		